Prospective Screening Programme for Malignant Tumors

• Conditions: Hematologic Tests; Malignant Tumor

• Registration Number: NCT04230200
• Lead Sponsor: Sun Yat-sen University

Brief Summary

In prospective part of study, the investigators have found that the parameters of routine blood tests can differentiate varieties of malignancy from healthy people.

The investigators enrolled healthy subjects and patients with malignancy that aged from 18 to 85，and collected their clinical data and blood tests result to build the model.And retrospectlly enroll healthy subjects and patients to test the model.

Detailed Description

Not available

Study Timeline

• Study Start: 2017-03-28
• Primary Completion: 2019-03-30
• Status Verified: 2020-01
• Study First Submitted: 2020-01-13
• Study First Submitted QC: 2020-01-13
• Last Update Submitted: 2020-01-17
• Study First Posted: 2020-01-18
• Last Update Posted: 2020-01-22
• Study Completion: 2020-03-30

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 10000

Inclusion Criteria

1. Asymptomatic persons between the ages of 18 to 80 years
2. Chinese ethnicity
3. After 3 year follow-up, diagnosed with no malignant disease
4. Subject underwent routine blood tests in our center

Exclusion Criteria

1.With a history of malignant disease

For the cohort of patients with malignancy

Inclusion Criteria:

1. diagnosis with the following malignant disease，breast cancer, lung cancer, gastric cancer， esophageal cancer，colorectal cancer，nasopharyngeal cancer，liver cancer and cervical cancer
2. Subject underwent routine blood tests in our center

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
sensitivity (true positive rate)	1 year	The proportion of persons with disease who have a positive test (positive test results among persons with disease)
Specificity (true negative rate)	1 year	The proportion of persons without disease who have a negative test (negative test results among persons without disease)

Trial Locations

Locations (1)

Sun Yat-sen University Cancer Center; 🇨🇳 Guangzhou, Guangdong, China